Adar1 Capital Management portfolio · Q4 2025
ADAR1 Capital Management, LLC · CIK 0001940272 ·13F filings on SEC EDGAR
In Q4 2025, ADAR1 Capital Management, LLC reported 270 positions worth $1.4B. Its largest holding was ABVX at 13.0% of the portfolio, and the top 10 made up 45%. This is the earliest quarter available here, so changes are not shown.
Portfolio map
Each box is a position sized by its value. There is no previous quarter here to compare changes. The smallest 230 positions are grouped as one box.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
ABVX ABIVAX SA-ADR | 13.05% | $7.90 | $99.02 | +1,152.9% | $130.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTGX PROTAGONIST THERAPEUTICS INC | 6.73% | $36.15* | $140.89 | +289.8% | $147.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ROIV ROIVANT SCIENCES LTD | 5.46% | $12.90* | $36.57 | +183.6% | $125.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMVT IMMUNOVANT INC | 4.63% | $19.22* | $33.78 | +75.8% | $83.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RNAM AVIDITY BIOSCIENCES INC | 2.90% | $69.33 | $72.13 | +4.0% | $39.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BOXX ALPHA ARCHITECT 1-3 MNTH BOX | 2.85% | $106.78 | $118.39 | +10.9% | $39.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPY SS SPDR S&P 500 ETF TRUST-US | 2.74% | $646.13 | $762.63 | +18.0% | $41.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CYTK CYTOKINETICS INC | 2.52% | $52.29* | $65.91 | +26.1% | $35.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SEPN SEPTERNA INC | 2.37% | $9.95 | $39.13 | +293.4% | $45.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABUS ARBUTUS BIOPHARMA CORP | 1.91% | $3.83* | $4.78 | +24.9% | $25.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZLAB ZAI LAB LTD-ADR | 1.61% | $23.03* | $26.34 | +14.4% | $32.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TERN TERNS PHARMACEUTICALS INC | 1.61% | $39.72 | $52.72 | +32.7% | $28.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTMX CYTOMX THERAPEUTICS INC | 1.31% | $2.54 | $2.72 | +7.2% | $11.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLDX CELLDEX THERAPEUTICS INC | 1.29% | $26.40 | $32.41 | +22.8% | $21M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RAPT RAPT THERAPEUTICS INC | 1.27% | $8.10 | $33.87 | +318.3% | $17.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IKT INHIBIKASE THERAPEUTICS INC | 1.21% | $2.80 | $2.06 | -26.7% | $16.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BBIO BRIDGEBIO PHARMA INC | 1.20% | $29.85* | $65.80 | +120.5% | $14M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MNPR MONOPAR THERAPEUTICS INC | 1.12% | $48.65 | $79.67 | +63.8% | $18.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PCVX VAXCYTE INC | 1.07% | $38.43 | $56.90 | +48.1% | $18M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRNX CRINETICS PHARMACEUTICALS IN | 1.06% | $43.32 | $37.42 | -13.6% | $11.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FULC FULCRUM THERAPEUTICS INC | 1.04% | $10.51* | $3.70 | -64.8% | $4.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRTA PROTHENA CORP PLC | 1.02% | $6.07 | $8.38 | +38.1% | $12.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LXEO LEXEO THERAPEUTICS INC | 1.02% | $6.72 | $3.38 | -49.7% | $4.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TSHA TAYSHA GENE THERAPIES INC | 1.01% | $2.03* | $4.87 | +140.0% | $12.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CDTX CIDARA THERAPEUTICS INC | 0.97% | $151.14 | $220.89 | +46.2% | $13.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IVA INVENTIVA SA - ADR | 0.93% | $4.65 | $3.69 | -20.6% | $10M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ESTA ESTABLISHMENT LABS HOLDINGS | 0.92% | $56.17 | $64.17 | +14.2% | $11M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIL SS SPDR BB 1-3M T-BILL ETF | 0.91% | $91.43* | $91.64 | +0.2% | $12.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
REPL REPLIMUNE GROUP INC | 0.89% | $5.40 | $13.24 | +145.1% | $16.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IONS IONIS PHARMACEUTICALS INC | 0.85% | $43.09 | $44.65 | +3.6% | $6.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMD REVOLUTION MEDICINES INC | 0.85% | $45.37 | $205.26 | +352.4% | $29.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMLX AMYLYX PHARMACEUTICALS INC | 0.79% | $3.77 | $29.10 | +671.5% | $25.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CGON CG ONCOLOGY INC | 0.79% | $29.67 | $70.89 | +138.9% | $18.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TFX TELEFLEX INC | 0.72% | $122.04 | $125.04 | +2.5% | $10.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IVVD INVIVYD INC | 0.71% | $1.10 | $0.87 | -20.9% | $3.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
REGN REGENERON PHARMACEUTICALS | 0.68% | $589.33 | $758.27 | +28.7% | $9.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XENE XENON PHARMACEUTICALS INC | 0.67% | $34.34 | $37.19 | +8.3% | $7.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EQ EQUILLIUM INC | 0.64% | $1.43 | $1.62 | +13.6% | $9.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SVRA SAVARA INC | 0.62% | $2.75 | $5.16 | +87.5% | $7.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MAZE MAZE THERAPEUTICS INC | 0.55% | $39.18 | $27.18 | -30.6% | $4.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
881624209 TEVA PHARMACEUTICAL INDS LTD | 0.54% | $14.93* | $33.88 | +126.9% | $8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CBIO CRESCENT BIOPHARMA INC | 0.53% | $11.86 | $14.59 | +23.0% | $8.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OVID OVID THERAPEUTICS INC | 0.51% | $1.63* | $2.49 | +52.9% | $10.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.50% | — | — | — | $6.8M | |
BLTE BELITE BIO INC - ADR | 0.47% | $159.96 | $169.82 | +6.2% | $6.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VRTX VERTEX PHARMACEUTICALS INC | 0.46% | $421.86 | $522.81 | +23.9% | $7.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BHF BRIGHTHOUSE FINANCIAL INC | 0.45% | $63.56 | $49.90 | -21.5% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVR ANTERIS TECHNOLOGIES GLOBAL | 0.45% | $4.97 | $7.77 | +56.4% | $9.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AAM AA MISSION ACQUISITION COR-A | 0.45% | $10.03 | $10.67 | +6.4% | $6.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TARA PROTARA THERAPEUTIC INC | 0.45% | $5.33 | $3.05 | -42.8% | $3.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FRNM FREENOME INC | 0.44% | $10.06 | $10.88 | +8.2% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DHR DANAHER CORP | 0.43% | $228.92 | $221.55 | -3.2% | $5.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLYM CLIMB BIO INC | 0.42% | $5.23 | $11.47 | +119.5% | $16.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QURE UNIQURE NV | 0.41% | $43.46 | $24.16 | -44.4% | $5.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 0.40% | $62.26 | $95.22 | +52.9% | $4.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OACCU OAKTREE ACQUISITION III LIFE | 0.40% | $10.14 | $10.89 | +7.4% | $5.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
04351P101 ASCENDIS PHARMA A/S | 0.40% | $196.64* | $228.73 | +16.3% | $5.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AGIO AGIOS PHARMACEUTICALS INC | 0.38% | $27.86 | $33.25 | +19.3% | $6.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPRB SPRUCE BIOSCIENCES INC | 0.37% | $87.11 | $48.58 | -44.2% | $2.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MLYS MINERALYS THERAPEUTICS INC | 0.36% | $22.53 | $25.13 | +11.5% | $3.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KRYS KRYSTAL BIOTECH INC | 0.36% | $181.75 | $332.56 | +83.0% | $6.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PALI PALISADE BIO INC | 0.35% | $2.35 | $1.35 | -42.6% | $2.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.32% | — | — | — | $4.3M | |
SPRY ARS PHARMACEUTICALS INC | 0.32% | $11.39 | $4.31 | -62.2% | $1.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIIB BIOGEN INC | 0.31% | $155.57 | $225.88 | +45.2% | $5.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAMS NEWAMSTERDAM PHARMA CO NV | 0.31% | $18.89 | $24.32 | +28.7% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AEXA AMERICAN EXCEPTIONALISM-CL A | 0.30% | $11.33 | $11.14 | -1.6% | $4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARWR ARROWHEAD PHARMACEUTICALS IN | 0.28% | $22.40* | $65.45 | +192.2% | $3.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
N0731H103 ATAI BECKLEY NV | 0.27% | $5.29 | $4.09 | -22.7% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRVS CORVUS PHARMACEUTICALS INC | 0.26% | $7.70 | $11.52 | +49.6% | $5.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JANX JANUX THERAPEUTICS INC | 0.25% | $25.66 | $17.28 | -32.7% | $4.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GLUE MONTE ROSA THERAPEUTICS INC | 0.25% | $7.41 | $11.93 | +61.0% | $2.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVDL AVADEL PHARMACEUTICALS LTD | 0.24% | $21.55 | $21.55 | 0.0% | $3.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTNM CONTINEUM THERAPEUTICS INC-A | 0.23% | $11.30 | $13.42 | +18.8% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EVMN EVOMMUNE INC | 0.23% | $17.12 | $8.26 | -51.8% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.23% | — | — | — | $3.1M | |
SNY SANOFI-ADR | 0.23% | $47.35 | $41.23 | -12.9% | $2.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRRK SCHOLAR ROCK HOLDING CORP | 0.23% | $40.24 | $48.32 | +20.1% | $3.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NKTR NEKTAR THERAPEUTICS | 0.22% | $50.08 | $60.54 | +20.9% | $4.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IWM ISHARES RUSSELL 2000 ETF | 0.22% | $246.17 | $277.89 | +12.9% | $3.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZURA ZURA BIO LTD | 0.22% | $3.34 | $4.16 | +24.4% | $2.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OKUR ONKURE THERAPEUTICS INC-A | 0.22% | $2.90 | $2.72 | -6.0% | $2.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
URGN UROGEN PHARMA LTD | 0.22% | $21.95 | $40.63 | +85.1% | $5.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LONA LEONABIO INC | 0.21% | $7.46 | $3.57 | -52.1% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 0.21% | $11.58 | $4.10 | -64.6% | $927.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELDN ELEDON PHARMACEUTICALS INC | 0.20% | $1.51 | $2.53 | +67.5% | $4.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
29286M105 ENGENE HOLDINGS INC | 0.20% | $9.03 | $6.81 | -24.6% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DVAX DYNAVAX TECHNOLOGIES CORP | 0.19% | $12.97 | $15.38 | +18.6% | $2.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INO INOVIO PHARMACEUTICALS INC | 0.19% | $1.74 | $1.83 | +5.2% | $2.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VRDN VIRIDIAN THERAPEUTICS INC | 0.18% | $14.42 | $20.59 | +42.8% | $1.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PHVS PHARVARIS NV | 0.17% | $23.70 | $31.72 | +33.8% | $2.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRBP CORBUS PHARMACEUTICALS HOLDI | 0.17% | $8.30 | $6.82 | -17.8% | $2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ATXS ASTRIA THERAPEUTICS INC | 0.17% | $5.87* | $13.09 | +123.1% | $2.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DCTH DELCATH SYSTEMS INC | 0.17% | $6.94* | $15.97 | +130.1% | $3.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EWTX EDGEWISE THERAPEUTICS INC | 0.17% | $21.62 | $40.60 | +87.8% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GRCE GRACE THERAPEUTICS INC | 0.16% | $3.20 | $2.15 | -32.9% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RGNX REGENXBIO INC | 0.15% | $8.79 | $8.38 | -4.7% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACLX ARCELLX INC | 0.15% | $76.95 | $114.82 | +49.2% | $3.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OLMA OLEMA PHARMACEUTICALS INC | 0.15% | $18.24 | $8.64 | -52.6% | $703.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MASI MASIMO CORP | 0.14% | $147.55 | $177.87 | +20.5% | $2.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
23256X407 CYBIN INC | 0.14% | $7.86 | $12.29 | +56.4% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLNO SOLENO THERAPEUTICS INC | 0.14% | $49.30 | $33.48 | -32.1% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABOS ACUMEN PHARMACEUTICALS INC | 0.14% | $1.21 | $2.22 | +82.8% | $2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACRS ACLARIS THERAPEUTICS INC | 0.14% | $2.33 | $5.26 | +125.3% | $3.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PFE PFIZER INC | 0.13% | $26.38* | $28.52 | +8.1% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIOA BIOAGE LABS INC | 0.13% | $4.07 | $7.09 | +74.1% | $961.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALKS ALKERMES PLC | 0.13% | $28.78 | $40.52 | +40.8% | $2.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GMED GLOBUS MEDICAL INC - A | 0.13% | $87.31 | $74.90 | -14.2% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALEC ALECTOR INC | 0.13% | $1.56 | $1.85 | +18.6% | $2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RCKT ROCKET PHARMACEUTICALS INC | 0.12% | $6.85 | $2.63 | -61.6% | $1.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WW WW INTERNATIONAL INC-NEW | 0.12% | $27.51 | $15.46 | -43.8% | $882.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.12% | — | — | — | $1.6M | |
SMMT SUMMIT THERAPEUTICS INC | 0.12% | $20.73 | $16.91 | -18.4% | $1.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CCIIU COHEN CIRCLE ACQUISITION COR | 0.11% | $10.28 | $10.46 | +1.8% | $1.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
868459108 SUPERNUS PHARMACEUTICALS | 0.11% | $48.77 | $43.04 | -11.8% | $1.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.11% | — | — | — | $1.4M | |
INSP INSPIRE MEDICAL SYSTEMS INC | 0.10% | $85.02 | $138.72 | +63.2% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NRIX NURIX THERAPEUTICS INC | 0.10% | $16.89 | $23.71 | +40.3% | $1.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JAZZ JAZZ PHARMACEUTICALS PLC | 0.10% | $150.04 | $231.52 | +54.3% | $1.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OABI OMNIAB INC | 0.10% | $1.99* | $2.46 | +23.3% | $1.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OMERPut OMEROS CORP | 0.09% | — | — | — | $1.3M |
TNGX TANGO THERAPEUTICS INC | 0.09% | $8.86 | $24.95 | +181.6% | $3.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADGM ADAGIO MEDICAL HOLDINGS INC | 0.09% | $1.04 | $0.15 | -85.3% | $177.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KNSA KINIKSA PHARMACEUTICALS INTE | 0.09% | $28.05 | $74.61 | +166.0% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYRE SPYRE THERAPEUTICS INC | 0.08% | $15.48 | $89.03 | +475.0% | $3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACET ADICET BIO INC | 0.08% | $8.42 | $7.14 | -15.2% | $918.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BMY BRISTOL-MYERS SQUIBB CO | 0.08% | $53.94 | $62.40 | +15.7% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TNYA TENAYA THERAPEUTICS INC | 0.08% | $0.71 | $0.60 | -15.2% | $908.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BSAAU BEST SPAC I ACQUISITION CORP | 0.08% | $10.04 | $10.40 | +3.6% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MRK MERCK & CO. INC. | 0.07% | $82.12 | $145.31 | +77.0% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INFQ INFLEQTION INC | 0.07% | $15.60 | $15.60 | 0.0% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EA ELECTRONIC ARTS INC | 0.07% | $201.70 | $205.04 | +1.7% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MCK MCKESSON CORP | 0.07% | $820.29 | $853.81 | +4.1% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTA CENTESSA PHARMACEUTICALS LTD | 0.07% | $14.81 | $39.72 | +168.1% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BNTX BIONTECH SE-ADR | 0.07% | $98.62 | $98.30 | -0.3% | $983K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.07% | — | — | — | $936.8K | |
VKTX VIKING THERAPEUTICS INC | 0.07% | $26.72* | $32.60 | +22.0% | $863.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
UTHR UNITED THERAPEUTICS CORP | 0.07% | $419.21 | $541.89 | +29.3% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PLYM PLYMOUTH INDUSTRIAL REIT INC | 0.07% | $21.88 | $21.88 | 0.0% | $898.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KVACFCall KEEN VISION ACQUISITION CORP | 0.06% | — | — | — | $881.3K |
FDMT 4D MOLECULAR THERAPEUTICS IN | 0.06% | $7.67 | $14.31 | +86.6% | $1.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DNLI DENALI THERAPEUTICS INC | 0.06% | $17.61 | $20.67 | +17.4% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XNCR XENCOR INC | 0.06% | $14.72 | $24.95 | +69.5% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LQDAPut LIQUIDIA CORP | 0.06% | — | — | — | $845K |
KLRS KALARIS THERAPEUTICS INC | 0.06% | $8.44 | $2.89 | -65.8% | $289K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QNRX QUOIN PHARMACEUTICALS LT-ADR | 0.06% | $14.43 | $14.43 | 0.0% | $840.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DYN DYNE THERAPEUTICS INC | 0.06% | $12.28 | $16.11 | +31.2% | $687.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
046353108 ASTRAZENECA PLC | 0.06% | $91.93 | $197.22 | +114.5% | $1.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GILD GILEAD SCIENCES INC | 0.06% | $122.74 | $149.05 | +21.4% | $993.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVTR AVANTOR INC | 0.06% | $11.96 | $15.05 | +25.8% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARE ALEXANDRIA REAL ESTATE EQUIT | 0.06% | $48.94 | $47.46 | -3.0% | $773.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LUNG PULMONX CORP | 0.06% | $2.41 | $1.91 | -20.8% | $678.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IBIO IBIO INC | 0.06% | $1.85 | $1.18 | -36.3% | $478.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TENX TENAX THERAPEUTICS INC | 0.06% | $6.51 | $56.70 | +771.1% | $3.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STRO SUTRO BIOPHARMA INC | 0.06% | $11.57 | $16.11 | +39.2% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BMRN BIOMARIN PHARMACEUTICAL INC | 0.06% | $63.71 | $60.00 | -5.8% | $774K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CMPX COMPASS THERAPEUTICS INC | 0.05% | $4.54 | $1.04 | -77.1% | $144.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VERA VERA THERAPEUTICS INC | 0.05% | $50.64 | $32.29 | -36.2% | $475.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KZR KEZAR LIFE SCIENCES INC | 0.05% | $0.77 | $7.42 | +859.6% | $871.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VTYX VENTYX BIOSCIENCES INC | 0.05% | $1.62* | $9.03 | +459.0% | $736.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.05% | — | — | — | $735.2K | |
| 0.05% | — | — | — | $717.9K | |
GH GUARDANT HEALTH INC | 0.05% | $68.15 | $178.36 | +161.7% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PHAT PHATHOM PHARMACEUTICALS INC | 0.05% | $8.62 | $7.30 | -15.3% | $313.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LRMR LARIMAR THERAPEUTICS INC | 0.05% | $2.89 | $3.19 | +10.6% | $593.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IDYA IDEAYA BIOSCIENCES INC | 0.05% | $27.21 | $38.42 | +41.2% | $768.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARVN ARVINAS INC | 0.05% | $7.02 | $7.74 | +10.2% | $449.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NUVL NUVALENT INC-A | 0.05% | $76.30 | $123.50 | +61.9% | $845K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASMB ASSEMBLY BIOSCIENCES INC | 0.05% | $25.94 | $23.49 | -9.4% | $463.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FWRD FORWARD AIR CORP | 0.05% | $25.00 | $13.51 | -46.0% | $359.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
38341P102 GOSSAMER BIO INC | 0.05% | $0.92* | $0.16 | -82.1% | $35K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENTA ENANTA PHARMACEUTICALS INC | 0.05% | $15.77 | $13.18 | -16.4% | $545.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ORKA ORUKA THERAPEUTICS INC | 0.05% | $10.33 | $83.29 | +706.6% | $1.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NGNE NEUROGENE INC | 0.05% | $12.07 | $27.82 | +130.4% | $852.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TECX TECTONIC THERAPEUTIC INC | 0.05% | $17.04 | $23.29 | +36.7% | $698.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRPT SAREPTA THERAPEUTICS INC | 0.05% | $41.01* | $18.22 | -55.6% | $525.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ISRG INTUITIVE SURGICAL INC | 0.04% | $566.36 | $406.63 | -28.2% | $414.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KYTX KYVERNA THERAPEUTICS INC | 0.04% | $9.40 | $8.63 | -8.2% | $495.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BABA ALIBABA GROUP HOLDING-SP ADR | 0.04% | $178.73 | $107.54 | -39.8% | $384.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDGL MADRIGAL PHARMACEUTICALS INC | 0.04% | $431.22 | $503.96 | +16.9% | $451K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CGEM CULLINAN THERAPEUTICS INC | 0.04% | $10.35 | $15.35 | +48.3% | $767.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTX CONTEXT THERAPEUTICS INC | 0.04% | $1.81 | $0.30 | -83.4% | $105.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GTERU GLOBA TERRA ACQUISITION CORP | 0.04% | $10.17 | $10.46 | +2.9% | $523K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
USFR WISDOMTREE FLOATING RATE TRE | 0.04% | $50.24* | $50.39 | +0.3% | $503.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
APLS APELLIS PHARMACEUTICALS INC | 0.04% | $49.67 | $40.23 | -19.0% | $804.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NTRA NATERA INC | 0.04% | $229.09 | $413.31 | +80.4% | $887.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BSX BOSTON SCIENTIFIC CORP | 0.04% | $95.35 | $43.65 | -54.2% | $218.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELVN ENLIVEN THERAPEUTICS INC | 0.03% | $15.40 | $45.84 | +197.7% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELAN ELANCO ANIMAL HEALTH INC | 0.03% | $22.63 | $22.39 | -1.1% | $447.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PYPD POLYPID LTD | 0.03% | $4.34 | $5.27 | +21.4% | $547.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GERN GERON CORP | 0.03% | $3.20* | $1.23 | -61.6% | $413.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRAX PRAXIS PRECISION MEDICINES I | 0.03% | $294.74 | $291.23 | -1.2% | $436.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NVCR NOVOCURE LTD | 0.03% | $12.92 | $12.93 | +0.1% | $439.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CORZ CORE SCIENTIFIC INC | 0.03% | $14.56 | $15.98 | +9.8% | $479.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OMER OMEROS CORP | 0.03% | $17.18 | $19.04 | +10.9% | $476K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.03% | — | — | — | $426K | |
KURA KURA ONCOLOGY INC | 0.03% | $7.31 | $10.71 | +46.6% | $428.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VTGN VISTAGEN THERAPEUTICS INC | 0.03% | $1.02 | $0.23 | -77.9% | $140.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BHVN BIOHAVEN LTD | 0.03% | $18.23 | $13.35 | -26.8% | $457.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KROS KEROS THERAPEUTICS INC | 0.03% | $12.72* | $11.40 | -10.4% | $214.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KPTI KARYOPHARM THERAPEUTICS INC | 0.03% | $6.95 | $9.77 | +40.6% | $488.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KIDS ORTHOPEDIATRICS CORP | 0.03% | $17.76 | $19.13 | +7.7% | $379.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCRX BIOCRYST PHARMACEUTICALS INC | 0.03% | $7.80 | $8.33 | +6.8% | $374.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AUPH AURINIA PHARMACEUTICALS INC | 0.03% | $15.95 | $16.20 | +1.5% | $356.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DAY DAYFORCE INC | 0.03% | $68.89 | $69.16 | +0.4% | $345.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TXMD THERAPEUTICSMD INC | 0.03% | $2.25* | $2.03 | -9.8% | $424.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KPRX KIORA PHARMACEUTICALS INC | 0.02% | $4.11 | $2.56 | -37.7% | $429.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JBIO JADE BIOSCIENCES INC | 0.02% | $15.43 | $14.05 | -8.9% | $295K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SGRY SURGERY PARTNERS INC | 0.02% | $23.75 | $16.80 | -29.3% | $336K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JD JD.COM INC-ADR | 0.02% | $34.98 | $26.60 | -24.0% | $266K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PCAPU PROCAP ACQUISITION CORP | 0.02% | $10.59 | $10.48 | -1.0% | $282.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DRUG BRIGHT MINDS BIOSCIENCES INC | 0.02% | $78.04 | $49.82 | -36.2% | $174.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IDXX IDEXX LABORATORIES INC | 0.02% | $676.53 | $522.19 | -22.8% | $208.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.02% | — | — | — | $268K | |
SPRO SPERO THERAPEUTICS INC | 0.02% | $1.44* | $2.33 | +62.0% | $265.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CATX PERSPECTIVE THERAPEUTICS INC | 0.02% | $2.75 | $2.75 | 0.0% | $261.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMMX IMMIX BIOPHARMA INC | 0.02% | $5.23 | $9.11 | +74.2% | $455.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
471871202 JASPER THERAPEUTICS INC | 0.02% | $1.83 | $0.42 | -77.0% | $58.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SNDX SYNDAX PHARMACEUTICALS INC | 0.02% | $21.01 | $18.80 | -10.5% | $225.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OGN ORGANON & CO | 0.02% | $9.47 | $13.70 | +44.6% | $479.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.02% | — | — | — | $243K | |
ANNX ANNEXON INC | 0.02% | $5.02 | $5.54 | +10.4% | $265.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PEPG PEPGEN INC | 0.02% | $2.84 | $2.42 | -14.9% | $89.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EOLS EVOLUS INC | 0.02% | $6.65 | $8.00 | +20.3% | $286.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACHV ACHIEVE LIFE SCIENCES INC | 0.02% | $2.95 | $8.09 | +174.0% | $386.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCAX BICARA THERAPEUTICS INC | 0.02% | $9.29 | $18.61 | +100.3% | $255.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.02% | — | — | — | $230K | |
RXST RXSIGHT INC | 0.02% | $10.42 | $9.80 | -5.9% | $213.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIST MILESTONE PHARMACEUTICALS IN | 0.01% | $2.02 | $0.87 | -57.1% | $86.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.01% | — | — | — | $195.6K | |
WHWK WHITEHAWK THERAPEUTICS INC | 0.01% | $2.42 | $3.76 | +55.4% | $291.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TRAW TRAWS PHARMA INC | 0.01% | $1.13 | $0.59 | -47.5% | $91.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KALV KALVISTA PHARMACEUTICALS INC | 0.01% | $9.79 | $20.13 | +105.7% | $201.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OTLKPut OUTLOOK THERAPEUTICS INC | 0.01% | — | — | — | $158K |
RLMD RELMADA THERAPEUTICS INC | 0.01% | $4.83 | $3.77 | -21.9% | $116.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
92941V308 VYNE THERAPEUTICS INC | 0.01% | $0.58 | $0.65 | +12.2% | $165.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
22053A107 QUINCE THERAPEUTICS INC | 0.01% | $1.48 | $0.10 | -93.1% | $4.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLN SILENCE THERAPEUTICS PLC-ADR | 0.01% | $17.78* | $10.93 | -38.5% | $258.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RXRX RECURSION PHARMACEUTICALS-A | 0.01% | $5.72 | $4.13 | -27.7% | $144.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VYGR VOYAGER THERAPEUTICS INC | 0.01% | $5.94* | $2.68 | -54.9% | $93.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
184492106 CLEANCORE SOLUTIONS INC | 0.01% | $0.26 | $0.26 | 0.0% | $135.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CMMB CHEMOMAB THERAPEUTICS LTD | 0.01% | $1.65 | $1.62 | -1.8% | $129.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.01% | — | — | — | $131.4K | |
PMVP PMV PHARMACEUTICALS INC | 0.01% | $1.56 | $1.67 | +6.9% | $168.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GBIO GENERATION BIO CO | 0.01% | $6.12 | $5.68 | -7.2% | $125.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NEUP NEUPHORIA THERAPEUTICS INC | 0.01% | $3.88 | $3.56 | -8.2% | $106.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLOV CLOVER HEALTH INVESTMENTS CO | 0.01% | $3.05 | $4.31 | +41.5% | $208.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.01% | — | — | — | $108.8K | |
ZNTL ZENTALIS PHARMACEUTICALS INC | 0.01% | $1.23 | $2.77 | +125.0% | $221.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
09077B104 BIOATLA INC | 0.01% | $0.57 | $0.16 | -71.6% | $29.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SABS SAB BIOTHERAPEUTICS INC | 0.01% | $2.75 | $3.17 | +15.1% | $83.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STICall SOLIDION TECHNOLOGY INC | 0.01% | — | — | — | $95.7K |
KYNB KYNTRA BIO INC | 0.01% | $8.78 | $6.65 | -24.3% | $69.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RZLT REZOLUTE INC | 0.01% | $4.30 | $4.14 | -3.7% | $160.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NMRA NEUMORA THERAPEUTICS INC | 0.01% | $1.79 | $0.60 | -66.7% | $30.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PLRX PLIANT THERAPEUTICS INC | 0.01% | $1.22 | $1.08 | -11.5% | $79.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LITS LITE STRATEGY INC | 0.01% | $2.42 | $1.32 | -45.5% | $88.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRD OPUS GENETICS INC | 0.01% | $2.01 | $4.84 | +140.8% | $193.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VTGNPut VISTAGEN THERAPEUTICS INC | 0.01% | — | — | — | $79.4K |
483119202 KALA BIO INC | 0.01% | — | $0.17 | — | $24.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VERU VERU INC | 0.01% | $2.14 | $2.66 | +24.3% | $93.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QTTB Q32 BIO INC | 0.00% | $3.32 | $8.27 | +149.1% | $165.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MREO MEREO BIOPHARMA GROUP PL-ADR | 0.00% | $0.42 | $0.33 | -20.8% | $49.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BMEA BIOMEA FUSION INC | 0.00% | $1.24 | $1.33 | +7.3% | $57.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASPCR A SPAC III ACQUISITION CORP | 0.00% | $0.14 | $0.10 | -28.4% | $21.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
002120202 ATYR PHARMA INC | 0.00% | $0.72 | $0.60 | -17.3% | $30.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRQR PROQR THERAPEUTICS NV | 0.00% | $5.30 | $1.66 | -68.7% | $16.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
44984F807 INVO FERTILITY INC. | 0.00% | $0.75 | $0.75 | 0.0% | $20.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IOBTQ IO BIOTECH INC | 0.00% | $0.61 | $0.61 | 0.0% | $15.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CHRS COHERUS ONCOLOGY INC | 0.00% | $0.73 | $1.21 | +65.5% | $12.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Dec 31, 2023, when our collected history starts, so the average starts from that quarter's price.
SEC filings for Q4 2025
- 13F-HR 0001940272-26-000002 · accepted Feb 17, 2026, 21:55 UTC
- 13F-HR/A 0001940272-26-000003 · accepted Feb 18, 2026, 19:09 UTC · RESTATEMENT